Trial · NCT02859441
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tabulation of Adverse Events | From Baseline to Week 52 | The total number of adverse events through Week 52. |
| Secondary | Tabulation of Adverse Events | From Baseline to Week 104 | The total number of adverse events, excluding natural progression of disease events, through Week 104. |
| Secondary | The Proportion of Participants Experiencing Reduction in Size of at Least One Retinal Capillary Hemangioma (RCH), in the Absence of Other Ablative Treatment (Assessed by Fundus Photography and Fluorescein Angiography (FA)) | From Baseline to Week 52 | The proportion of participants experiencing a reduction in size of at least one RCH in the study eye, in the absence of other ablative treatment as assessed by fundus photography and fluorescein angiography (FA), between Baseline and Week 52. |
| Secondary | The Proportion of Participants Experiencing Reduction in Size of at Least One RCH, in the Absence of Other Ablative Treatment (Assessed by Fundus Photography and Fluorescein Angiography [FA]) | From Baseline to Week 104 | The proportion of participants experiencing a reduction in size of at least one RCH in the study eye, in the absence of other ablative treatment as assessed by fundus photography and fluorescein angiography (FA), between Baseline and Week 104. |
| Secondary | Proportion of Participants Undergoing Ablative Treatment of RCH or Ocular Surgery | From Baseline to Week 52 | The proportion of participants undergoing ablative treatment of RCH or ocular surgery in the study eye between Baseline and Week 52. |
| Secondary | Proportion of Participants Undergoing Ablative Treatment of RCH or Ocular Surgery | From Baseline to Week 104 | The proportion of participants undergoing ablative treatment of RCH or ocular surgery in the study eye between Baseline and Week 104. |
| Secondary | Proportion of Participants With Successful Ablative Treatment of RCH | From Baseline to Week 52 | The proportion of participants with successful ablative treatment of RCH in the study eye between Baseline and Week 52. |
| Secondary | Proportion of Participants With Successful Ablative Treatment of RCH | From Baseline to Week 104 | The proportion of participants with successful ablative treatment of RCH in the study eye between Baseline and Week 104. |
| Secondary | Mean Change in Visual Acuity | Baseline and Week 52 | Mean change in visual acuity in the study eye from Baseline as compared to Week 52 as measured using the Electronic Early Treatment of Diabetic Retinopathy Study (ETDRS) Visual Acuity (EVA) Testing protocol. Acuity is measured as letters read using an electronic ETDRS program. |
| Secondary | Mean Change in Visual Acuity | Baseline and Week 104 | Mean change in visual acuity in the study eye from Baseline as compared to Week 104 as measured using the Electronic Early Treatment of Diabetic Retinopathy Study (ETDRS) Visual Acuity (EVA) Testing protocol. Acuity is measured as letters read using an electronic ETDRS program. |
| Secondary | The Proportion of Participants Experiencing Moderate Vision Loss (Defined as a Loss of Greater Than or Equal to 15 Letters From Baseline on Electronic Visual Acuity [EVA] Testing) | From Baseline to Week 52 | The proportion of participants experiencing moderate vision loss in the study eye (defined as a loss of greater than or equal to 15 letters from baseline on Electronic Visual Acuity \[EVA\] testing) between Baseline and Week 52. |
| Secondary | The Proportion of Participants Experiencing Moderate Vision Loss (Defined as a Loss of Greater Than or Equal to 15 Letters From Baseline on Electronic Visual Acuity [EVA] Testing) | From Baseline to Week 104 | The proportion of participants experiencing moderate vision loss in the study eye (defined as a loss of greater than or equal to 15 letters from baseline on Electronic Visual Acuity \[EVA\] testing) between Baseline and Week 104. |
| Secondary | Change in Size of RCH (Measured by Fundus Photography and FA) | From Baseline to Week 52 | Number of participants who experienced increased, decreased, or mixed change in the size of RCH in the study eye between Baseline and Week 52 (measured by fundus photography and FA). |
| Secondary | Change in Size of RCH (Measured by Fundus Photography and FA) | From Baseline to Week 104 | Number of participants who experienced increased, decreased, or mixed change in the size of RCH in the study eye between Baseline and Week 104 (measured by fundus photography and FA). |
| Secondary | Change in Exudation (Measured by Fundus Photography, Optical Coherence Tomography (OCT) and FA) | From Baseline to Week 52 | Number of participants who experienced increased, decreased, or mixed change in exudation in the study eye between Baseline and Week 52 (measured by fundus photography, optical coherence tomography \[OCT\] and FA). |
| Secondary | Change in Exudation (Measured by Fundus Photography, Optical Coherence Tomography [OCT] and FA) | From Baseline to Week 104 | Number of participants who experienced increased, decreased, or mixed change in exudation in the study eye between Baseline and Week 104 (measured by fundus photography, optical coherence tomography \[OCT\] and FA). |
| Secondary | Change in Epiretinal Proliferation, Fibrosis or Retinal Traction (Assessed by OCT and Fundus Photography) | From Baseline to Week 52 | Number of participants who experienced increased, decreased, or mixed change in epiretinal proliferation, fibrosis or retinal traction in the study eye between Baseline and Week 52 (assessed by OCT and fundus photography). |
| Secondary | Change in Epiretinal Proliferation, Fibrosis or Retinal Traction (Assessed by OCT and Fundus Photography) | From Baseline to Week 104 | Number of participants who experienced increased, decreased, or mixed change in epiretinal proliferation, fibrosis or retinal traction in the study eye between Baseline and Week 104 (assessed by OCT and fundus photography). |
| Secondary | Proportion of Participants With Appearance of One or More New RCH | From Baseline to Week 52 | The proportion of participants with appearance of one or more new RCH in the study eye between Baseline and Week 52. |
| Secondary | Proportion of Participants With Appearance of One or More New RCH | From Baseline to Week 104 | The proportion of participants with appearance of one or more new RCH in the study eye between Baseline and Week 104. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02859441/registered